Mahasweta Mitra

Experienced Public Health Professional with extensive experience in translating complex population-level data into regulatory, clinical, and policy-relevant insights across federal, academic, nonprofit, and global health environments. Strategic leader with an established record of leading multidisciplinary research and operations spanning vaccine safety surveillance, pharmacoepidemiology, health economics and outcomes research (HEOR), and clinical trial operations development across FDA-, CDC-, and CMS-aligned initiatives, with demonstrated success in shaping evidence used for public health decision-making, program evaluation, and regulatory action. Recognized leadership in managing cross-functional teams, coordinating large-scale data partnerships, and guiding analytic and scientific workflows across programming, clinical, and policy stakeholders, while also producing peer-reviewed publications, delivering conference presentations, and supporting strategic health programs focused on quality improvement, health equity, and population health impact.

Senior Research Analyst | Data & Policy Analyst | Data Systems Programmer - Acumen, LLC - Burlingame, CA

(2019-07)

• Directed epidemiologic research and real-world evidence programs for federal healthcare agencies, including the FDA, CDC, and CMS, through observational studies that assessed vaccine safety, medication utilization, healthcare outcomes, and population health trends across Medicare, Medicaid, commercial claims, and distributed healthcare databases.
• Evaluated comparative safety outcomes and pulmonary embolism risk among Medicare beneficiaries through analyses that examined simultaneous versus sequential administration of COVID-19, RSV, and influenza vaccines.
• Advanced pediatric COVID-19 vaccine safety monitoring under the FDA Biologics Effectiveness and Safety (BEST) Initiative through active surveillance of adverse events of special interest and Medicaid-based pharmacoepidemiology studies that assessed utilization patterns of long-acting injectable atypical antipsychotics.
• Strengthened regulatory-grade evidence generation through Common Data Model implementation, Sentinel distributed data network participation, ETL verification, and data quality initiatives that enhanced data integrity and research reliability.
• Produced protocols, technical reports, scientific presentations, manuscripts, and stakeholder deliverables that informed regulatory and public health decisions, including co-authored publications in JAMA Pediatrics and JAMA Network Open.
• Coordinated cross-functional COVID-19 surveillance operations across research teams by aligning tracking systems for diagnoses, testing, specimen collection, and mortality indicators under national, state, and local coding standards.
• Directed technical consensus-building discussions with the American Psychiatric Association to refine the Psychoses episode-based cost measure for improved methodological accuracy and performance evaluation.
• Created efficient SAS-based programs using advanced macro language constructs to process large-scale healthcare datasets to enhance performance across complex data management workflows and improve computational efficiency.
• Produced technical documentation, user guides, and formal reports alongside programmers and research teams, while strengthening transparency, reproducibility, and usability of analytical systems.
• Promoted from Data Systems Programmer and Data and Policy Analyst roles to Senior Research Analyst for demonstrating progressive career growth and expanded analytical and technical leadership responsibilities through consistent delivery of high-impact data solutions and research-driven insights.

Research Assistant – Bill & Melinda Gates Foundation Funded Study - University of Michigan - Ann Arbor, MI

(2019-01 - 2019-04)

• Assessed the impact of a pilot intervention on persistent anemia among adolescent girls and women in Ghana, and identified key implementation barriers and factors affecting program uptake and sustainability within the fish processing industry context.
• Analyzed large-scale household survey and public health datasets using R software to generate descriptive statistics and evaluate health outcomes, behavioral risk factors, and intervention effectiveness at the population level.
• Produced bi-weekly data reports and technical deliverables translating analytical findings into clear, evidence-based insights for stakeholders, including Innovations for Poverty Action and the University of Ghana, to support public health planning and program design.

Research Intern – Independent Qualitative/Quantitative Study - Israel Ministry of Health: Department of Nutrition Division - Jerusalem District, Israel

(2018-05 - 2018-07)

• Directed a mixed-methods public health study on obesity among ethnic minority and religious diaspora communities in Israel to examine socioeconomic and structural determinants of health disparities across affected populations.
• Examined the 2015–2016 MABAT adolescent nutrition survey using quantitative analytical methods to evaluate the relationship between socioeconomic status and childhood obesity outcomes in Israel.
• Synthesized epidemiological findings into policy-oriented recommendations and technical reports through collaboration with Ministry of Health researchers and public health practitioners.

Clinical Research Associate - Novo Nordisk India - Bengaluru, India

(2015-06 - 2017-06)

• Oversaw clinical trial monitoring across 20+ government and private investigational sites for Phase II/III diabetes studies, while ensuring protocol compliance, patient safety, and achievement of 95% enrollment targets ahead of schedule.
• Delivered structured protocol, GCP, and safety reporting training to more than 40 investigators and site personnel, while strengthening adherence to regulatory standards and reducing protocol deviations across participating centers.
• Accelerated study activation timelines by 50% through coordination of 5+ regulatory and ethics submissions, which streamlined documentation workflows and enhanced stakeholder engagement across study sites.
• Represented Novo Nordisk India at the global mid-trial monitors meeting in Dubai for the Ryzodeg-Ramadan study, contributing to cross-regional alignment on monitoring strategies and sharing operational best practices across international affiliates.

Master of Public Health - Global Health Epidemiology - University of Michigan, School of Public Health (2019-04)

Bachelor of Technology - Biotechnology - Vellore Institute of Technology (VIT) (2015-05)